CD8 response; DRibbles; GVAX; immune-monitoring; prostate cancer
The immune system plays an essential role in eradicating cancer in concert with various treatment modalities. In the absence of autologous tumor material, no standardized method exists to assess T cell responses against the many antigens that may serve as cancer rejection antigens. Thus, development of methods to screen for therapy-induced anti-tumor responses is a high priority that could help tailor therapy. Here we tested whether a tumor-derived antigen source called DRibbles®, which contain a pool of defective ribosomal products (DRiPs), long-lived and short-lived proteins (SLiPs) and danger-associated molecular patterns (DAMPs), can be used to identify tumor-associated antigen (TAA)-specific responses in patients before or after immunotherapy treatment. Protein content, gene expression and non-synonymous - single nucleotide variants (ns-SNVs) present in UbiLT3 DRibbles were compared with prostate adenocarcinomas and the prostate GVAX vaccine cell lines (PC3/LNCaP). UbiLT3 DRibbles were found to share proteins, as well as match tumor sequences for ns-SNVs with prostate adenocarcinomas and with the cell lines PC3 and LNCaP. UbiLT3 DRibbles were used to monitor anti-tumor responses in patients vaccinated with allogeneic prostate GVAX. UbiLT3-DRibble-reactive CD8
Earle A. Chiles Research Institute
van de Ven, Rieneke; Hilton, Traci L; Hu, Hong-Ming; Dubay, Christopher J; Haley, Daniel; Paustian, Christopher; Puri, Sachin; Urba, Walter; Curti, Brendan; Aung, Sandra; and Fox, Bernard A, "Autophagosome-based strategy to monitor apparent tumor-specific CD8 T cells in patients with prostate cancer." (2018). Articles, Abstracts, and Reports. 916.